benzimidazoles

Summary

Summary: Compounds with a BENZENE fused to IMIDAZOLES.

Top Publications

  1. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
  2. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
  3. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
  4. ncbi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
  5. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
  6. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
  7. ncbi Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase
    Simon A Hawley
    Division of Molecular Physiology University of Dundee, Dundee, Scotland, United Kingdom
    Cell Metab 2:9-19. 2005
  8. ncbi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
  9. ncbi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
  10. ncbi Telmisartan to prevent recurrent stroke and cardiovascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 359:1225-37. 2008

Research Grants

  1. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
  2. Oxidative Stress in Oral Streptococci
    Robert E Marquis; Fiscal Year: 2010
  3. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2002
  4. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2010
  5. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2011
  6. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2005
  7. ANALYSIS OF AH RECEPTOR LIGAND BINDING SPECIFICITY
    Michael Denison; Fiscal Year: 2002
  8. Oxidative Stress in Oral Streptococci
    Robert Marquis; Fiscal Year: 2007
  9. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
  10. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009

Detail Information

Publications287 found, 100 shown here

  1. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  2. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  3. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  4. ncbi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
    ..FUNDING: Boehringer Ingelheim...
  5. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  6. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  7. ncbi Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase
    Simon A Hawley
    Division of Molecular Physiology University of Dundee, Dundee, Scotland, United Kingdom
    Cell Metab 2:9-19. 2005
    ..Our results suggest a potential Ca(2+)-dependent neuroprotective pathway involving phosphorylation and activation of AMPK by CaMKKbeta...
  8. ncbi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  9. ncbi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009...
  10. ncbi Telmisartan to prevent recurrent stroke and cardiovascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 359:1225-37. 2008
    ..We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke...
  11. ncbi ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Cherrie K Donawho
    Abbott Laboratories, Abbott Park, Illinois 60064 6074, USA
    Clin Cancer Res 13:2728-37. 2007
    ..To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888...
  12. ncbi A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:14228-33. 2004
    ....
  13. ncbi In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
    Mami Ojima
    Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
    J Pharmacol Exp Ther 336:801-8. 2011
    ..Its tight receptor binding might be expected to produce potent and long-lasting antihypertensive effects in preclinical and clinical settings...
  14. ncbi Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2705-11. 2009
    ..It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies...
  15. ncbi Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter
    John A Cairns
    University of British Columbia, Vancouver, British Columbia, Canada
    Can J Cardiol 27:74-90. 2011
    ..Alternatives to antithrombotic therapies are briefly discussed...
  16. ncbi The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
    George L Bakris
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 13:81-8. 2011
    ..0 to -0.1; P=.038), while AZL-M 40 mg was noninferior to OLM-M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL-M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM-M...
  17. ncbi Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Thromb Haemost 105:721-9. 2011
    ..The risk of bleeding and safety profiles were similar...
  18. ncbi Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Hans Christoph Diener
    Department of Neurology, University Hospital Essen, Essen, Germany
    Lancet Neurol 9:1157-63. 2010
    ..We aimed to assess the effects of dabigatran compared with warfarin in the subgroup of patients with previous stroke or transient ischaemic attack...
  19. ncbi Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective
    S V Sorensen
    United BioSource Corporation, Bethesda, Maryland, USA
    Thromb Haemost 105:908-19. 2011
    ..This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients...
  20. ncbi Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate
    Neil S Roskell
    Neil Roskell, RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK
    Thromb Haemost 104:1106-15. 2010
    ..There was no indication of increased intracranial or extracranial haemorrhage with dabigatran etexilate compared to antiplatelet agents...
  21. ncbi The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
    ..Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects...
  22. ncbi Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial
    Toshio Ogihara
    Osaka University Graduate School of Medicine, Osaka, Japan
    Hypertension 51:393-8. 2008
    ..We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine...
  23. ncbi In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
    Wolfgang Wienen
    Department of Pulmonary Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, 88397 Biberach, Germany
    Thromb Haemost 98:155-62. 2007
    ..These data suggest that dabigatran is a potent, selective thrombin inhibitor and an orally active anticoagulant as the prodrug, dabigatran etexilate...
  24. ncbi The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques
    Christopher J French
    Department of Medicine, Cardiovascular Research Institute, University of Vermont, Burlington, VT, USA
    J Cardiovasc Pharmacol 58:143-8. 2011
    ..Accordingly, the suppression of PAI-1 expression by AZL-M may attenuate the evolution of atherosclerotic plaques vulnerable to rupture...
  25. ncbi Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    M Burnier
    Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Int Med Res 37:1662-79. 2009
    ..A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients...
  26. ncbi Estimation of the cost of large-scale school deworming programmes with benzimidazoles
    A Montresor
    Department of Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland
    Trans R Soc Trop Med Hyg 104:129-32. 2010
    ....
  27. ncbi Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker
    Takashi Kajiya
    Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan
    J Hypertens 29:2476-83. 2011
    ..Although azilsartan is considered to be an unusually potent angiotensin II type 1 (AT1) receptor antagonist, little is known about the potential pleiotropic effects of this molecule...
  28. ncbi Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors
    Elena V Efimova
    Ludwig Center for Metastasis Research, The University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 70:6277-82. 2010
    ..PARP inhibition markedly enhanced IRIF persistence and increased breast cancer cell senescence both in vitro and in vivo, arguing for targeting IRIF resolution as a novel therapeutic strategy...
  29. ncbi Renal protection in diabetes: lessons from ONTARGET
    Eberhard Ritz
    Universitat Erlangen, Medizinische Klinik IV, Erlangen, Germany
    Cardiovasc Diabetol 9:60. 2010
    ....
  30. ncbi Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
    Paul P Szotek
    Pediatric Surgical Research Laboratories, Department of Surgery, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 103:11154-9. 2006
    ..In the future, individualized therapy must incorporate analysis of the stem cell-like subpopulation of ovarian cancer cells when designing therapeutic strategies for ovarian cancer patients...
  31. ncbi Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
    Keiji Kusumoto
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Eur J Pharmacol 669:84-93. 2011
    ..These results suggest that azilsartan medoxomil is a potent angiotensin II receptor blocker that has an attractive pharmacological profile as an antihypertensive agent...
  32. ncbi Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records
    Yayoi Nishida
    Division of Genomic Epidemiology and Clinical Trials, Advanced Medical Research Center, Nihon University School of Medicine, 30 1 Oyaguchi Kamimachi, Itabashi ku, Tokyo 173 8610, Japan
    Cardiovasc Diabetol 9:38. 2010
    ..Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan...
  33. ncbi Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 13:467-72. 2011
    ..These findings suggest that AZL-M could provide higher rates of hypertension control compared with other ARBs in the class...
  34. ncbi The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
    Udai Banerji
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Cancer Res 16:1613-23. 2010
    ..In part B, the aim was to compare the pharmacokinetic profile of the new Hyd-Sulfate capsule with the initial AZD6244 free-base suspension and further characterize the pharmacodynamic profile and efficacy of the new formulation...
  35. ncbi Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  36. ncbi Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs
    Kwang Kon Koh
    Vascular Medicine and Atherosclerosis Unit, Cardiology, Gil Medical Center, Gachon University, Incheon, Republic of Korea
    Int J Cardiol 140:73-81. 2010
    ..This is not explained by changes in blood pressure alone. We hypothesized that distinct vascular and metabolic effects of anti-hypertensive drugs may explain these differential effects...
  37. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    ..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis...
  38. ncbi The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Stefan Blech
    Boehringer Ingelheim Pharma GmbH and Co KG, Department of Drug Metabolism and Pharmacokinetics, Biberach, Germany
    Drug Metab Dispos 36:386-99. 2008
    ..o. administration of dabigatran etexilate and that the potential for clinically relevant interactions between dabigatran and drugs metabolized by cytochrome P450 is low...
  39. ncbi AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical
    Barry R Davies
    Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    Mol Cancer Ther 6:2209-19. 2007
    ..Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel...
  40. ncbi Formation of cellular projections in neural progenitor cells depends on SK3 channel activity
    Stefan Liebau
    Department of Anatomy and Cell Biology, University of Ulm, Ulm, Germany
    J Neurochem 101:1338-1350. 2007
    ..Both effects could be prevented by the pre-incubation of NPCs with ScTX. Our study gives first evidence that the formation and prolongation of filopodia in NPCs is, at least in part, effectively induced and regulated by SK3 channels...
  41. ncbi Long-term regulation of ENaC expression in kidney by angiotensin II
    Kathleen T Beutler
    Laboratory of Kidney and Electrolyte Metabolism, NHLBI, National Institutes of Health, Bethesda, MD 20892-1603, USA
    Hypertension 41:1143-50. 2003
    ..The results support the view that the angiotensin II receptor regulates ENaC abundance, consistent with a role for angiotensin II in regulation of collecting duct function...
  42. ncbi Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  43. ncbi Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  44. ncbi Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies
    David H G Smith
    Blood Press Monit 8:111-7. 2003
    ..Both telmisartan and losartan were found to be safe and well tolerated. CONCLUSIONS: Telmisartan 40/80 mg is superior to losartan 50/100 mg in controlling DBP and SBP during the last 6 h of the 24-h dosing interval...
  45. ncbi Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..The 2 highest doses of dabigatran suppress D-dimer concentrations. Serious liver toxicity was not seen. The significance of the increase of DTB2 concentrations in dabigatran-treated patients needs resolution...
  46. ncbi Spontaneous changes in mitochondrial membrane potential in cultured neurons
    J F Buckman
    Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
    J Neurosci 21:5054-65. 2001
    ..We hypothesize that these DeltaPsi(m) fluctuations are dependent on the proper functioning of the mitochondria and reflect mitochondria alternating between the active and inactive states of oxidative phosphorylation...
  47. ncbi Combined human and porcine mass chemotherapy for the control of T. solium
    H H Garcia
    Department of Microbiology, Universidad Peruana Cayetano Heredia, San Martin de Porras, Lima, Peru
    Am J Trop Med Hyg 74:850-5. 2006
    ..Mass chemotherapy was effective in decreasing infection pressure in this hyperendemic area. However, the magnitude of the effect was small and did not attain the goal of eliminating transmission...
  48. ncbi Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension
    Maria E Marketou
    Cardiology Department, Heraklion University Hospital, Crete, Greece
    Am J Cardiol 107:59-63. 2011
    ..Our findings may provide new insights into the cardiovascular protection of telmisartan in hypertensives...
  49. ncbi Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice
    Shiho Fujisaka
    The First Department of Internal Medicine, University of Toyama, Toyama, Japan
    Endocrinology 152:1789-99. 2011
    ..In conclusion, telmisartan improves insulin sensitivity and modulates adipose tissue macrophage polarization to an antiinflammatory M2 state in high-fat-fed mice...
  50. ncbi Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 14:6877-85. 2008
    ..S. Food and Drug Administration's Exploratory Investigational New Drug Application. Performance of the study design, needle biopsy procedure, and validated pharmacodynamic assay were evaluated in human tumor xenograft models...
  51. ncbi Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole
    C S Sikasunge
    School of Veterinary Medicine, University of Zambia, P O Box 32379, Lusaka, Zambia
    Vet Parasitol 158:57-66. 2008
    ....
  52. ncbi Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer
    Thomas D Penning
    Cancer Research, Pharmacokinetics, GPRD, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 52:514-23. 2009
    ....
  53. ncbi Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
    C E Mogensen
    Department of Medicine, M, Kommunehospitalet, University Hospital, DK 8000 Aarhus C, Denmark
    BMJ 321:1440-4. 2000
    ..To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes...
  54. ncbi Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
    Ramzi E L Féghali
    The Cardiovascular Institute, Paris, France
    Vasc Health Risk Manag 3:165-71. 2007
    ..To study the effect of candesartan cilexetil (CC) in the management of blood pressure (BP) in diabetic and non-diabetic hypertensive patients...
  55. ncbi CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
    Suzanne Trudel
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital and McLaughlin Centre of Molecular Medicine, University of Toronto, 620 University Ave, Rm 8 204, Toronto, ON, Canada M5G 2C1
    Blood 105:2941-8. 2005
    ..Finally, therapeutic efficacy of CHIR-258 was demonstrated in a xenograft mouse model of FGFR3 MM. These studies support the clinical evaluation of CHIR-258 in MM...
  56. ncbi Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation
    Kai Kappert
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Strasse 3 4, Berlin, Germany
    Hypertension 54:738-43. 2009
    ..Our data show that sufficient serum levels of EXP3179 are present under losartan treatment. PPARgamma activation by AT1R-blockers may translate into synergistic beneficial actions in monocytes...
  57. ncbi Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons
    J Wolfart
    Medical Research Council, Anatomical Neuropharmacology Unit, Department of Pharmacology, Oxford University, Oxford OX1 3TH, United Kingdom
    J Neurosci 21:3443-56. 2001
    ..This provides a cellular framework to understand the functional consequences of altered SK3 expression, a candidate disease mechanism for schizophrenia...
  58. ncbi Antioxidants prevent ethanol-associated apoptosis in fetal rhombencephalic neurons
    Angeline M Antonio
    Department of Cell Biology, Neurobiology, and Anatomy, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA
    Brain Res 1204:16-23. 2008
    ..e., those cultured in the absence of ethanol. These studies showed that several classes of antioxidants can exert neuroprotection against ethanol-associated apoptosis in fetal rhombencephalic neurons...
  59. ncbi The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases
    Rebecca L Hurley
    Departments of Medicine and Biochemistry, Dartmouth Medical School and the Department of Biological Sciences, Dartmouth College, Hanover, NH 03755, USA
    J Biol Chem 280:29060-6. 2005
    ..These data indicate that the CaMKKs function in intact cells as AMPKKs, predicting wider roles for these kinases in regulating AMPK activity in vivo...
  60. ncbi Nuclear condensation and free radical scavenging: a dual mechanism of bisbenzimidazoles to modulate radiation damage to DNA
    Urmila Tawar
    Dr B R Ambedkar Center for Biomedical Research, University of Delhi, Delhi, 110007, India
    Mol Cell Biochem 305:221-33. 2007
    ..In the present study, benzimidazoles DMA and TBZ showed marked radioprotection through drug-induced compaction of chromatin and direct quenching of ..
  61. ncbi In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
    Sang Hoon Lee
    Department of Pharmacology, Chiron Corp, Emeryville, California, USA
    Clin Cancer Res 11:3633-41. 2005
    ..CHIR-258 exhibits properties that make it a promising candidate for clinical development in a variety of solid and hematologic malignancies...
  62. ncbi Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Jeffrey M Albert
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 13:3033-42. 2007
    ..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation...
  63. ncbi Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials
    Vladimir Trkulja
    Department of Pharmacology, Zagreb University School of Medicine, Salata 11, 10000 Zagreb, Croatia
    Croat Med J 51:113-23. 2010
    ..To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20618 patients...
  64. ncbi A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Thorac Oncol 5:1630-6. 2010
    ..AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  65. ncbi A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway
    Nathalie Bouquier
    Centre de Recherche de Biochimie Macromoleculaire, Universites Montpellier I et II, CNRS, 34293 Montpellier, France
    Chem Biol 16:657-66. 2009
    ..This study introduces a selective cell active inhibitor of the Trio/RhoG/Rac1 pathway and validates RhoGEFs as druggable targets...
  66. ncbi Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial
    Kazuwa Nakao
    Department of Medicine and Medical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Hypertens Res 33:600-6. 2010
    ..Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity...
  67. ncbi Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Ave, Suite G36, Wynnewood, PA 19096, USA
    Circulation 122:2246-53. 2010
    ..The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients...
  68. ncbi Structural study of selected polyhalogenated benzimidazoles (protein kinase CK2 inhibitors) by nuclear quadrupole double resonance, X-ray, and density functional theory
    J N Latosińska
    Faculty of Physics, Adam Mickiewicz University Umultowska 85, 61 614 Poznan, Poland
    J Phys Chem A 114:563-75. 2010
    Protein kinase CK2 inhibitors, polyhalogenated benzimidazoles, have been studied experimentally in solid state by NMR-NQR double resonance and X-ray and theoretically by the density functional theory (DFT)...
  69. ncbi Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression
    Jiu Chang Zhong
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Vascular Biology, Shanghai Institute of Hypertension, Shanghai 200025, China
    Regul Pept 166:90-7. 2011
    ..In conclusion, telmisartan treatment attenuates vascular hypertrophy in SHR by the modulation of ACE2 and profilin-1 expression with a marked reversal of ERK1/2 and JNK phosphorylation signaling pathways...
  70. ncbi Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial
    Stella Maria G Kyvelou
    Hypertension Unit, 1st Cardiology Department, Athens University, Hippokration Hospital, Greece
    Hellenic J Cardiol 47:21-8. 2006
    ..This study was conducted to evaluate blood pressure control and the plasma lipid profile in hypertensive patients after six months' treatment with ARB...
  71. ncbi High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering
    M Shargorodsky
    Department of Endocrinology, Wolfson Medical Center, Holon and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Atherosclerosis 197:303-10. 2008
    ..Treatment with high doses of Candesartan improves arterial stiffness to a greater extent than conventional doses of Candesartan, despite comparable changes in blood pressure...
  72. ncbi Laboratory toxicity test and post-exposure feeding inhibition using the giant freshwater prawn Macrobrachium rosenbergii
    Kriengkrai Satapornvanit
    Department of Fishery Biology, Faculty of Fisheries, Kasetsart University, Bangkhen, Chatuchak, Bangkok 10900, Thailand
    Chemosphere 74:1209-15. 2009
    ..This study demonstrated that the M. rosenbergii could also be used as a test animal to detect the effects of different chemical contaminants in aquatic environments...
  73. ncbi Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats
    Maxim Krikov
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Hypertens 26:544-52. 2008
    ....
  74. ncbi Inhibition of intestinal Cl- secretion by clotrimazole: direct effect on basolateral membrane K+ channels
    D C Devor
    Department of Cell Biology and Physiology, University of Pittsburgh, Pennsylvania 15261, USA
    Am J Physiol 273:C531-40. 1997
    ..We demonstrate that clotrimazole blocks the intestinal KCa, thereby inhibiting Cl- secretion. These results suggest that clotrimazole may be useful as an antidiarrheal...
  75. ncbi A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
    G G Wulf
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 98:1166-73. 2001
    ..They also suggest a mechanism by which SP cells could escape the effects of cytostatic drugs and might eventually contribute to leukemia relapse. (Blood. 2001;98:1166-1173)..
  76. ncbi Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials
    Rudy Bilous
    Newcastle University, Newcastle upon Tyne, United Kingdom
    Ann Intern Med 151:11-20, W3-4. 2009
    ..Microalbuminuria in diabetes is strongly predictive of nephropathy, end-stage renal disease, and premature cardiovascular morbidity and mortality. Effective preventive therapies are therefore a clinical priority...
  77. ncbi Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2
    Piotr Zien
    Regulatory Biology and Functional Genomics Research Group, Siebens-Drake Medical Research Institute, Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada N6A 5C1
    Biochim Biophys Acta 1754:271-80. 2005
    ..Finally, development of shRNA strategies for the selective knockdown of the CK2alpha and CK2alpha' isoforms reinforces the foregoing results, indicating that inhibition of CK2 leads to attenuation of proliferation...
  78. ncbi Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
    Hung Huynh
    Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore 169610, Singapore
    Mol Cancer Ther 6:138-46. 2007
    ..Targeted inhibition of the MEK-ERK pathway with AZD6244 may represent an alternative approach for the treatment of this disease...
  79. ncbi [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension]
    S Uen
    Abteilung für Hypertonie und Angiologie, Medizinische Universitäts Poliklinik der Universität Bonn
    Dtsch Med Wochenschr 132:81-6. 2007
    ..blood pressure and ST-segment depression during daily life of patients with treated but not controlled arterial hypertension (blood pressure taken at doctor's practice (3)140/90 mmHg, despite being on at least two antihypertensive drugs)..
  80. ncbi Markers for benzimidazole resistance in human parasitic nematodes?
    Roger K Prichard
    Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste Anne de Bellevue, Quebec, Canada, H9X 3V9
    Parasitology 134:1087-92. 2007
    ....
  81. ncbi Anthelmintic resistance in nematodes: extent, recent understanding and future directions for control and research
    R K Prichard
    Institute of Parasitology, McGill University, Macdonald College, Ste Anne de Bellevue, QC Canada
    Int J Parasitol 20:515-23. 1990
    ..has now been reported to all of the broad spectrum anthelmintic types currently available, namely to the benzimidazoles, levamisole/morantel and to ivermectin...
  82. ncbi Constrictor and dilator effects of angiotensin II on cerebral arterioles
    Jean-Martin Vincent
    Laboratoire de Pharmacologie, , , 5 rue Albert Lebrun, 54000 Nancy, France
    Stroke 36:2691-5. 2005
    ....
  83. ncbi Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress
    Vijayakumar Sukumaran
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
    Eur J Pharmacol 652:126-35. 2011
    ....
  84. ncbi Effect of substitution on the antimycobacterial activity of 2-(substituted benzyl)sulfanyl benzimidazoles, benzoxazoles, and benzothiazoles--a quantitative structure-activity relationship study
    Oldrich Pytela
    Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University Pardubice, Pardubice, Czech Republic
    Chem Pharm Bull (Tokyo) 59:179-84. 2011
    ..of substitution on the antimycobacterial activity of the previously published 2-(substituted benzyl)sulfanyl benzimidazoles, benzoxazoles, and benzothiazoles has been analyzed by the methods of multidimensional analysis (exploratory ..
  85. ncbi Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action
    Arun Prasath Lakshmanan
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan
    Free Radic Res 45:575-84. 2011
    ..These findings suggest that Ang-II plays a significant role in DN and telmisartan would be beneficial in reducing oxidative stress and fibrosis in STZ-induced DN...
  86. ncbi [An experimental study of expression of angiotension converting enzyme 2 in myocardium and effect of telmisartan treatment in pressure-overloaded rats]
    Li Jun Wang
    Department of Cardiology, The Affiliated Baoan Hospital of Nanfang Medical University, Shenzhen 518101, Guangdong, China
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 20:218-22. 2008
    ..To study the effect of hypertension and telmisartan treatment on the protein and gene expression of cardiac angiotensin-converting enzyme 2 (ACE2) in pressure-overloaded rats...
  87. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006
    ..CONCLUSIONS: Our data provide a relevant preclinical basis for clinical trials of CHIR-258 in FGFR3-positive MM patients...
  88. ncbi Partial sequence of the beta-tubulin of Histomonas meleagridis and the activity of benzimidazoles against H. meleagridis in vitro
    Rüdiger Hauck
    Institute of Poultry Diseases, Faculty of Veterinary Medicine, Free University Berlin, Königsweg 63, 14163, Berlin, Germany
    Parasitol Res 104:1183-9. 2009
    ..b>Benzimidazoles are antiparasitic drugs, and some of them are licensed for use in food-producing animals...
  89. ncbi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    ..We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population...
  90. ncbi Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and Trichinella spiralis
    Francisco Hernández-Luis
    Facultad de Quimica, Departamento de Farmacia, UNAM, Mexico, DF 04510, Mexico
    Eur J Med Chem 45:3135-41. 2010
    ..In the in vivo model against T. spiralis, compounds 1b and 1e showed good activity against the adult phase at 75 mg/Kg. However, against the muscle larvae stage, only compound 1f exhibited in vivo antiparasitic efficacy...
  91. ncbi In vivo pharmacological manipulation of small conductance Ca(2+)-activated K(+) channels influences motor behavior, object memory and fear conditioning
    Kyle A Vick
    Interdisciplinary Program in Neuroscience, Florida Atlantic University, Boca Raton, FL 33431 0991, USA
    Neuropharmacology 58:650-9. 2010
    ..These results suggest that SK channel activation impairs the encoding of non-aversive memory but not memory for aversive events. These data support converging evidence that SK channels regulate cellular mechanisms of memory encoding...
  92. ncbi Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue
    Hiroshi Kudo
    Third Department of Internal Medicine, University of Toyama, Toyama, Japan
    Liver Int 29:988-96. 2009
    ..The aim of this study was to investigate the efficacy and mechanisms of Tel on a murine NASH model...
  93. ncbi Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet
    Haiyan Jin
    Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami Kogushi 1 1 1 Ube, Yamaguchi 755 8505, Japan
    Biochem Biophys Res Commun 364:801-7. 2007
    ..Tel inhibited HSCs activation and proliferation. These results suggested that Tel could be a promising drug for NASH related liver fibrosis...
  94. ncbi Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy
    Gerd Bönner
    MEDIAN Kliniken, Bad Krozingen, Germany
    Blood Press Suppl 2:22-30. 2008
    ..To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy...
  95. ncbi Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany
    BMC Cardiovasc Disord 8:30. 2008
    ....
  96. ncbi Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
    Hirofumi Makino
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-Okayama, Japan
    Diabetes Care 30:1577-8. 2007
  97. ncbi Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study
    Kasper Rossing
    Steno Diabetes Center, Gentofte, Denmark. Faculty of Health Science, University of Aarhus, Aarhus, Denmark
    Diabetes Care 26:150-5. 2003
    ..05 versus placebo). CONCLUSIONS: The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction in albuminuria, in hypertensive type 2 diabetic patients with nephropathy...
  98. ncbi CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
    Daniel E Lopes de Menezes
    Chiron Corp, Biopharma Research and Development, Emeryville, California 94608, USA
    Clin Cancer Res 11:5281-91. 2005
    ..CONCLUSIONS: Our data indicate that CHIR-258 may be an effective therapy in FLT3-associated AML and warrants clinical trials...
  99. ncbi Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazoles
    Z Kazimierczuk
    Institute of Chemistry, Agricultural University, 159C Nowoursynowska Street, 02 787 Warsaw, Poland
    Eur J Med Chem 40:203-8. 2005
    A series of substituted 2-polyfluoroalkyl and 2-nitrobenzylsulphanyl benzimidazoles was synthesized...
  100. ncbi Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis
    Haleh Talaie
    Education Development Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Clin Exp Pharmacol Physiol 31:777-82. 2004
    ..No cases of toxic hepatitis were observed. 6. In conclusion, oral administration of 10 mg/kg of the human pharmaceutical preparation of triclabendazole for 1-3 days is safe and effective in the treatment of human fascioliasis...
  101. ncbi Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses
    Peter Borowski
    Abteilung fur Virologie, Bernhard Nocht Institut fur Tropenmedizin, Hamburg, Germany
    Eur J Biochem 270:1645-53. 2003
    ..The halogeno benzimidazoles and benzotriazoles included in this study are excellent lead compounds for the development of more potent ..

Research Grants109 found, 100 shown here

  1. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
    ..Hypertension candidate genes will then be isolated using cDNA screening techniques to identify genes expressed in the brain, adrenal gland, or kidney that map within this chromosome region. ..
  2. Oxidative Stress in Oral Streptococci
    Robert E Marquis; Fiscal Year: 2010
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  3. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2002
    ..indicate that MDR induction is the most likely explanation for the intrinsic resistance of Candida species to benzimidazoles and for the antagonistic activity between compounds that induce MDR (albendazole and sulfadiazine) and ..
  4. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2010
    ..tubulin/microtubules and has hypothesized that a certain class of taxanes (microtubule-stabilizer) and benzimidazoles (tubulin polymerization inhibitors) should inhibit the depolymerization or polymerization of FtsZ from ..
  5. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2011
    ..tubulin/microtubules and has hypothesized that a certain class of taxanes (microtubule-stabilizer) and benzimidazoles (tubulin polymerization inhibitors) should inhibit the depolymerization or polymerization of FtsZ from ..
  6. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2005
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  7. ANALYSIS OF AH RECEPTOR LIGAND BINDING SPECIFICITY
    Michael Denison; Fiscal Year: 2002
    ..The mechanism by which benzimidazoles, selected pesticides and other chemicals activate the AhR in a "ligand-independent manner" and the ability of ..
  8. Oxidative Stress in Oral Streptococci
    Robert Marquis; Fiscal Year: 2007
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  9. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  10. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  11. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 1999
    ..W. Lawrence Drew (UCSF) and from Dr. Alejo Erice (University of Minnesota). ..
  12. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2010
    ..Detailed understanding of the genetic mechanisms of resistance will improve the design of suitable new drug structures and antiviral targets. ..
  13. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2007
    ....
  14. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2003
    ....
  15. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  16. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
    ....
  17. Sir2 regulation and chemical modulation
    Anthony Sauve; Fiscal Year: 2007
    ....
  18. Sir2 regulation and chemical modulation
    Anthony A Sauve; Fiscal Year: 2010
    ..abstract_text> ..
  19. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC WOODWARD HOPF; Fiscal Year: 2010
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  20. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC HOPF; Fiscal Year: 2007
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  21. NITRIC OXIDE SYNTHASE IN THE JUXTAGLOMERULAR APPARATUS
    CHRISTOPHER WILCOX; Fiscal Year: 2009
    ..abstract_text> ..
  22. REGULATION OF RENAL FUNCTION AND BP BY THROMBOXANE
    CHRISTOPHER WILCOX; Fiscal Year: 2002
    ....
  23. DEVELOPMENT OF A LIVE ATTENUATED HSV-2 VACCINE
    Mark Prichard; Fiscal Year: 2002
    ..In addition further in vitro characterization will enable high quality clinical trial material to be produced for IND enabling primate studies and early Phase I human trials. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  24. GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE
    CHARLES RUDIN; Fiscal Year: 2002
    ..Understanding the molecular basis of the various cellular responses to DNA damage is relevant to the design of both chemopreventative and therapeutic anticancer strategies. ..
  25. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..